Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

The Hexosamine Biosynthesis Pathway: Regulation and Function

Paneque A., Fortus H., Zheng J., Werlen G., Jacinto E.

Narrative Review on Systemic / IV, published in Genes (Basel) (2023) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Genes (Basel) (2023)
Reported sample size
—
Source database
Europe PMC
PMID
37107691
PMCID
PMC10138107
DOI
10.3390/genes14040933
Citations
169

Abstract (original English)

The hexosamine biosynthesis pathway (HBP) produces uridine diphosphate- N -acetyl glucosamine, UDP-GlcNAc, which is a key metabolite that is used for N - or O -linked glycosylation, a co- or post-translational modification, respectively, that modulates protein activity and expression. The production of hexosamines can occur via de novo or salvage mechanisms that are catalyzed by metabolic enzymes. Nutrients including glutamine, glucose, acetyl-CoA, and UTP are utilized by the HBP. Together with availability of these nutrients, signaling molecules that respond to environmental signals, such as mTOR, AMPK, and stress-regulated transcription factors, modulate the HBP. This review discusses the regulation of GFAT, the key enzyme of the de novo HBP, as well as other metabolic enzymes that catalyze the reactions to produce UDP-GlcNAc. We also examine the contribution of the salvage mechanisms in the HBP and how dietary supplementation of the salvage metabolites glucosamine and N -acetylglucosamine could reprogram metabolism and have therapeutic potential. We elaborate on how UDP-GlcNAc is utilized for N -glycosylation of membrane and secretory proteins and how the HBP is reprogrammed during nutrient fluctuations to maintain proteostasis. We also consider how O -GlcNAcylation is coupled to nutrient availability and how this modification modulates cell signaling. We summarize how dereg

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HexosaminesGlucosamineProtein Processing, Post-TranslationalGlycosylationTOR Serine-Threonine Kinases

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research